|
|
|
|
Dual Action Drug Fights High Blood Pressure, Heart Disease
(Ivanhoe Newswire) -- A new dual-action drug, called LCZ696, is well tolerated and provides significantly greater reductions in blood pressure than the established angiotensin receptor blocker (ARB) valsartan.LCZ696 might be superior to standard ARBs and...
|
|
|
Angio dose related to patient size, disease complexity
_ Angio dose related to patient size, disease complexity.
|
|
|
ACC.10: St. Jude Medical Showcases Cardiac Care Solutions
Jude Medical showcases robust portfolio of products for cardiac care at ACC.10 conference at the Georgia World Congress Center St.Jude Medical , Inc. announced it will display products and technologies from the company's wide array of clinical solutions in...
|
|
|
St. Jude Medical to Showcase Robust Portfolio of Products for Cardiac Care at American College of Cardiology (ACC) 2010
Jude Medical, Inc.announced it will display products and technologies from the companys wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010. Jude Medical is pleased to...
|
|
|
St. Jude Medical to Showcase Robust Portfolio of Products for Cardiac Care at American College of Cardiology (ACC) 2010
PAUL, Minn.-- (BUSINESS WIRE) -- St.Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the companys wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm...
|
|
|
Advanced Visualization Adds 5D Functional Analytics
New advanced visualization technology allows clinicians to automatically apply supercomputing algorithms for the analysis of internal organs, vessels, tumors and other regions of interest in multiple dimensions, from 2D to 5D.Ziosoft Inc. offers...
|
|
|
St. Jude Medical to Showcase Robust Portfolio of Products for Cardiac Care at American College of Cardiology (ACC) 2010
PAUL, Minn.--(BUSINESS WIRE)--St.Jude Medical, Inc. (NYSE: STJ) today announced it will display products and technologies from the companys wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm...
|
|
|
St. Jude Medical to Showcase Robust Portfolio of Products for Cardiac Care at American College of Cardiology (ACC) 2010
Companies mentioned in this article: St.Jude Medical, Inc. PAUL, Minn. -- (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the companys wide array of clinical solutions in the...
|
|
|
New Introducer Product Line from St. Jude Medical Offers Reliable Access and Facilitates Arterial Closure
Engage Family offers physicians state-of-the-art introducers capable of facilitating both femoral and radial access ST.PAUL, Minn.-- (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) clearance...
|
|
|
New Introducer Product Line from St. Jude Medical Offers Reliable Access and Facilitates Arterial Closure
PAUL, Minn.--(BUSINESS WIRE)--St.Jude Medical, Inc. (NYSE: STJ) today announced U.S. Food and Drug Administration (FDA) clearance and European CE Mark approval for the Engage? and Engage TR? Introducers? Introducers are the starting point of...
|
|
|
St. Jude Medical's Engage, Engage TR Introducers Receive FDA, European CE Mark Approval - Update
3/11/2010 9:35 AM ET RELATED NEWS Trade STJ now with TOP MARKET NEWS (RTTNews) - St.Jude Medical, Inc. (STJ: News ) announced Thursday that its introducers, Engage and Engage TR, device used as a starting point of cardiac catheterization, won clearance...
|
|
|
New Introducer Product Line from St. Jude Medical Offers Reliable Access and Facilitates Arterial Closure
Jude Medical, Inc.(NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) clearance and European CE Mark approval for the Engage„ and Engage TR„ Introducers. Introducers are the starting point of cardiac catheterization for...
|
|
|
New Introducer Product Line from St. Jude Medical Offers Reliable Access and Facilitates Arterial Closure
Companies mentioned in this article: St.Jude Medical, Inc. PAUL, Minn. -- (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) clearance and European CE Mark approval for the Engage and Engage...
|
|
|
St. Jude Medical (STJ) Receives U.S. FDA Clearance and European CE Mark for Engage and Engage TR
Jude Medical, Inc.(NYSE: STJ) today announced U.S. Food and Drug Administration (FDA) clearance and European CE Mark approval for the Engage and Engage TR Introducers. Introducers are the starting point of cardiac catheterization for diagnostic and...
|
|
|
Initial experience of removal of 10-French sheaths using the 8-French angio-seal vascular closure device. Marc
_ Initial experience of removal of 10-French sheaths using the 8-French angio-seal vascular closure device.Marc.
|
|
|
Agfa Displays Surgical Procedure - Cardiac Examinations: ECR10
Agfa HealthCare announces that it will be displaying its SEPARIO angio set, for angiography and cardiology examinations, including stenting procedures and electrophysiology procedures at ECR 2010.Agfa HealthCare first introduced its new line of...
|
|
|
Angiotech Pharmaceuticals, Inc. (USA)
Pharmaceuticals, Inc.(USA) Research MSN @import @import @import @import .initial h.companyName Loading... SiteSearch.msnBind('#search', letters My My S&P 00: ,8. hange: 0.00% has been added to your watchlist. You can find it in the watchlist tab on...
|
|
|
Study Shows C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute, Successive Attacks of Hereditary Angioed
Additional data presented at the 2010 AAAAI Annual Meeting confirms long half-life of C1-INH protects HAE patients from rebound attacks NEW ORLEANS, March 1 /PRNewswire/ -- C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that...
|
|
|
Study Shows C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute, Successive Attacks of Hereditary Angioed
Additional data presented at the 2010 AAAAI Annual Meeting confirms long half-life of C1-INH protects HAE patients from rebound attacks NEW ORLEANS, March 1 /PRNewswire/ -- C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that...
|
|
|
Study Shows C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute, Successive Attacks of Hereditary Angioed
Additional data presented at the 2010 AAAAI Annual Meeting confirms long half-life of C1-INH protects HAE patients from rebound attacks NEW ORLEANS, March 1 /PRNewswire/ -- C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that...
|
|
|
Pre-Angio Beta Blockade Contraindicated for Many
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Siemens Healthcare Introduces New Functional Imaging Application
Siemens Healthcare has developed a new software application, which enables the visualisation of parenchymal blood flow during minimally invasive interventions in the brain for the first time.The feature assists neuroradiologists in the treatment of stroke...
|
|
|
Faster stroke treatment with application for imaging of blood flow in brain
Siemens Healthcare has developed a new software application that enables the visualisation of parenchymal blood flow during minimally invasive interventions in the brain for the first time.This feature will help neuroradiologists to shorten the time from...
|
|
|
NEJM Publishes Trial Results Demonstrating Bard FLAIR(R) Endovascular Stent Graft is Superior to Balloon Angio
MURRAY HILL, N.J., Feb.10 /PRNewswire-FirstCall/ -- C. Bard, Inc. (NYSE: BCR) today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR Endovascular Stent Graft maintains the patency of dialysis...
|
|
|
NEJM Publishes Trial Results Demonstrating Bard FLAIR(R) Endovascular Stent Graft Is Superior To Balloon Angio
Bard, Inc.(NYSE: BCR) announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone.
|
